Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Safety and Efficacy Study for Patients With Nonsense Mutation Cystic Fibrosis Previously Treated With Ataluren (PTC124)

NCT02107859 is registered in ClinicalTrials.gov with PTC Therapeutics as lead sponsor.

NCT NCT02107859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02107859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Safety and Efficacy Study for Patients With Nonsense Mutation Cystic Fibrosis Previously Treated With Ataluren (PTC124)
Lead sponsor
PTC Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
May 23, 2014
Completion date
June 5, 2017
Enrollment
61 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis